Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10381978" target="_blank" >RIV/00216208:11110/18:10381978 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/18:10381978

Výsledek na webu

<a href="https://pmr.lf1.cuni.cz/media/pdf/pmr_2018119020085.pdf" target="_blank" >https://pmr.lf1.cuni.cz/media/pdf/pmr_2018119020085.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14712/23362936.2018.8" target="_blank" >10.14712/23362936.2018.8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease

Popis výsledku v původním jazyce

Parkinson&apos;s disease is a neurodegenerative disorder with the pathological accumulation of alpha synuclein in the brain and peripheral nerve tissue. Early stages of synucleinopathies, often present clinically with rapid eye movement (REM) sleep disorder (RBD). Clinical markers that indicate early progression from RBD to manifest synucleinopathies include abnormal dopamine transporter (DAT) imaging, motor and non-motor symptoms. Despite the high diagnostic strength of DAT imaging and motor abnormalities, they are not the earliest biomarkers. Non-motor signs of neurodegeneration such as colour vision and olfaction abnormalities are detectable by clinical examination as early as 20 years before disease onset. Detailed analysis of olfactory and colour vision dysfunction can provide valuable information regarding brain pathologies, further specifying clinical phenotypes, and giving clues to underlying pathophysiological mechanisms in Parkinson&apos;s disease and related disorders.

Název v anglickém jazyce

Olfaction and Colour Vision: What Can They Tell Us about Parkinson's Disease

Popis výsledku anglicky

Parkinson&apos;s disease is a neurodegenerative disorder with the pathological accumulation of alpha synuclein in the brain and peripheral nerve tissue. Early stages of synucleinopathies, often present clinically with rapid eye movement (REM) sleep disorder (RBD). Clinical markers that indicate early progression from RBD to manifest synucleinopathies include abnormal dopamine transporter (DAT) imaging, motor and non-motor symptoms. Despite the high diagnostic strength of DAT imaging and motor abnormalities, they are not the earliest biomarkers. Non-motor signs of neurodegeneration such as colour vision and olfaction abnormalities are detectable by clinical examination as early as 20 years before disease onset. Detailed analysis of olfactory and colour vision dysfunction can provide valuable information regarding brain pathologies, further specifying clinical phenotypes, and giving clues to underlying pathophysiological mechanisms in Parkinson&apos;s disease and related disorders.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/NV16-28914A" target="_blank" >NV16-28914A: Porucha chování v REM spánku – klinika, souvislosti a vývoj</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Prague Medical Report

ISSN

1214-6994

e-ISSN

—

Svazek periodika

119

Číslo periodika v rámci svazku

2-3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

12

Strana od-do

85-96

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85056256343